Cargando…
Synthesis and biological evaluation of geldanamycin–ferulic acid conjugate as a potent Hsp90 inhibitor
A novel geldanamycin–ferulic acid conjugate LZY228 was prepared and evaluated for anti-proliferation activity on human cancer cell line MDA-MB-231. Compound LZY228 exhibited potent cytotoxicity with IC(50) value of 0.27 μM, which was more potent than 17-AAG. Hepatotoxicity test in mice demonstrated...
Autores principales: | Li, Zhenyu, Jia, Lejiao, Tang, Hui, Shen, Yuemao, Shen, Chengwu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076653/ https://www.ncbi.nlm.nih.gov/pubmed/35542888 http://dx.doi.org/10.1039/c9ra08665j |
Ejemplares similares
-
LZY3016, a novel geldanamycin derivative, inhibits tumor growth in an MDA-MB-231 xenograft model
por: Li, Zhenyu, et al.
Publicado: (2023) -
Development of the first geldanamycin-based HSP90 degraders
por: Wurnig, Silas, et al.
Publicado: (2023) -
An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitors – potential therapeutics in cancer and neurodegeneration
por: Kitson, Russell R. A., et al.
Publicado: (2013) -
HSP90 Inhibitor Geldanamycin as a Radiation Response Modificator in Human Blood Cells
por: Stankova, Katia, et al.
Publicado: (2015) -
17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition
por: LIN, ZHIYUAN, et al.
Publicado: (2015)